Gene editing, with which Vertex Pharmaceuticals Incorporated has seen success, is one thing; base editing may be another. Shares in Verve Therapeutics, Inc. cratered on the NASDAQ after data presented at the American Heart Association on 12 November revealed that two patients treated with Verve’s base-editing anti-cholesterol therapy VERVE-101 suffered severe cardiovascular events.
Key Takeaways
- Verve’s first base-editing therapy seems to work in patients with high cholesterol and heart disease
The company’s stock price fell 40% the day after the data were released, opening at $9.50 on 13 November, though...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?